Autism Spectrum Disorder
Conditions
Keywords
neuroimaging, mri, phenotype, heritability, genes
Brief summary
This project is structured around a central study called Study of genetic factors involved in autism and related conditions (Genes and Autism study, sponsor: INSERM). This study explores clinical and genetic aspects of ASD (autism spectrum disorders) and is complemented with several ancillary studies (such as this one) which will use the data of the main study and will allow an extensive review of phenotypes associated with ASD. In this ancillary study, we will go on the acquisition of anatomical, diffusion and functional MRI in subjects with ASD, relatives and controls. Our group has already performed several neuroanatomical studies of ASD. IWe recruited since 2010 more than 600 subjects (proponents, relatives and controls) to better understand the implication of brain abnormalities in ASD. This study involves specialized teams in neuroiamging based at INSERM, NeuroSpin (CEA), Robert Debré Hospital (APHP) and Pasteur Institute Our main objective is to identify structural, connectivity and functional peculiarities in subjects with ASD Secondary objectives include: * the identification of familial heritability patterns of ASD * correlate data obtained in brain imaging with genetic data * assess specificity and statistical reproducibility of the obtained results
Interventions
OTHERNeuroimaging (MRI)
Multimodal magnetic resonance imaging
Sponsors
APHP
Institut Pasteur
Commissariat A L'energie Atomique
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
24 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
* for patients: * being included in the main study C16-89 - Study of genetic factors involved in ASD and related disorders * having an ASD fulfilling DSM-5 diagnostic criteria (APA, 2012). Diagnosis will be done by a clinical expert, with the support of structured instruments (ADI-R, ADOS-2) * having at least 24 Months * being affiliated with the French health insurance * having signed the informed consent (by proposant or by legal tutors if the subject is \<18 or under legal custody) * for relatives * being included in the main study C16-89 - Study of genetic factors involved in ASD and related disorders * having at least 24 Months * being affiliated with the French health insurance * having signed the informed consent (by proposant or by legal tutors if the subject is \<18 or under legal custody) * for controls * being included in the main study C16-89 - Study of genetic factors involved in ASD and related disorders * having at least 24 Months * being affiliated with the French health insurance * having signed the informed consent (by proposant or by legal tutors if the subject is \<18 or under legal custody) Non-inclusion criteria: * for all subjects * severe mental retardation (IQ\<35 or developmental age\<18 months) * medical condition (either psychiatric or physical) not compatible with an inclusion * MRI counter indication * Current pregnancy or breastfeeding, assessed by questionnaire * Not willing to be informed of a brain abnormality diagnosed with MRI * for the relatives \*discovery of non filiation during the genetic analyses * for controls * Neurological history (except mental retardation) * Personal history of (checked with DIGS for Adults, Diagnostic Interview for Genetic Studies, Numberger et coll., 1994, or Kiddie SADS, Kiddie Schedule for Disorders and Schizophrenia for School Age Children, Orvaschel et coll., 1982): schizophrenia, addiction, bipolar disorder, recurrent depression (\> 2 episodes lifetime), severe, not stabilized anxiety disorder, history of episodes of epilepsy, significant inflammatory disease of immunosuppressive medication
Exclusion criteria
* for patients: ASD diagnosis not confirmed by assessments after the inclusion * for all subjects: discovery of a counter indication to MRI during the exam (e.g. claustrophobia)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3DT1 MRI derived variables | Day 0 | Cortical folding Cortical thickness Cortical surface Cortical, white matter and subcortical volumes |
| Resting state fMRI derived variables | Day 0 | Whole-brain BOLD signal correlations |
| Task based fMRI derived variables | Day 0 | BOLD activation signals BOLD signal correlations |
| Diffusion MRI derived variables | Day 0 | Fractional anisotropy and mean diffusivity NODDI derived variables |
| quantitative T1 and quantitative T2 MRI | Day 0 | Myelin Water Fraction |
Countries
France
Contacts
Primary ContactRichard Delorme, M.D, Ph.D
Backup ContactJosselin Houenou, M.D, Ph.D
Outcome results
None listed